Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-869 plus paclitaxel versus paclitaxel plus placebo in first-line recurrent or metastatic breast cancer
NL-OMON32901Phase 2Withdrawn
- Sponsor
- Abbott Laboratories
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Paclitaxel + ABT-869 with Paclitaxel + placebo (2 arms). Primary endpoint: Progression-free survival. Planned start Nov 2008; status: withdrawn.
02
Drugs
linifanibpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON32901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32901.